Dr. Igor Splawski Appointed Chief Scientific Officer of Yarrow Biotechnology | citybiz

NEW YORK–(BUSINESS WIRE)–Yarrow Biotechnology, Inc.A RTW Investments, L.P Incubated company developing nucleic acid therapies and other modalities for serious genetically defined diseases, including those of the central nervous system, today announced the appointment of Dr. Igor Splawski as Scientific Director. Dr. Splawski was previously Chief Scientific Officer and a member of the Executive Committee of CureVac (Nasdaq: CVAC), where he led a team of 150 scientists who developed mRNA technology and mRNA vaccines and therapeutics for infectious diseases, cancer and rare indications.

Dr. Splawski brings 30 years of experience in genetic discovery as well as research and development of new therapies for disease. Igor and his teams have taken over 20 compounds into clinical trials, with 11 currently in Phase I-III trials. Prior to serving as Chief Scientific Officer of CureVac, Dr. Splawski spent fifteen years at the Novartis Institutes for BioMedical Research (NIBR). While serving as Executive Director and Site Chief at the NIBR Biologics Center, he led a team of more than 100 scientists who discovered and developed antibody and protein therapies. Earlier in his career, Dr. Splawski served as an assistant professor at Harvard Medical School, where he identified new genes and mechanisms for cardiac arrhythmias and associated disorders, including cardiomyopathy, muscle disease, deafness and autism. He has also held positions at Boston Children’s Hospital and Howard Hughes Medical Institute.

Dr. Splawski holds a PhD in human genetics from the University of Utah and a master’s degree in biotechnology from Sofia University. He is inventor of 28 patents and author of 23 research publications inCell,Science,New England Journal of Medicine,NatureGeneticsANDPNAS.

Dr Splawski is recognized as a leading figure in the development of complex human genetic testing, protein bioproducts and RNA therapeutics and we are thrilled to welcome him to Yarrow, he said Peter Fong, PhD, Chief Executive Officer of Yarrow Biotechnology and Partner and Chief Development Officer at RTW. Igor’s deep experience will be invaluable to the company as we deliver impactful therapies for disorders with unmet needs.

It is an honor to join the amazing team at Yarrow and help bring transformative nucleic acid therapies to patients, said Dr. Splawski. Yarrows’ science aims to tackle the most pressing CNS diseases, many of which currently have suboptimal treatments and no cure. I am thrilled to help Yarrow realize his vision and help improve the lives of patients in need.

About Yarrow Biotechnology, Inc.

Yarrow focuses on the development of nucleic acid therapies for serious and genetically defined diseases, including those of the central nervous system. Yarrow was founded and incubated by RTW Investments in New York and is rooted in the fund’s long experience and commitment to solving genetic diseases.

About RTW Investments, LP

RTW Investments, LP (“RTW”) is a global lifecycle investment firm focused on identifying transformative and disruptive innovations in the biopharmaceutical and medical technologies sectors. As a leading partner to industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to support emerging medical therapies and the companies and/or academics who develop them. RTW is headquartered in New York with offices in London and Shanghai.

For more information about RTW, visit www.RTWfunds.com

#Igor #Splawski #Appointed #Chief #Scientific #Officer #Yarrow #Biotechnology #citybiz
Image Source : www.citybiz.co

Leave a Comment